Heterogeneity of Melanoma with Stem Cell Properties

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Melanoma Research

Background:

• Metastatic melanoma has a low cure rate and poor median survival.
• Tumor heterogeneity, including cancer stem cell (CSC) populations with drug resistance markers, complicates treatment.
• Melanoma cell subpopulations can resist standard therapies, leading to relapse and metastasis.

Purpose of the Study:

• To highlight recent findings on CSC markers in aggressive melanoma.
• To investigate the potential of targeting the embryonic morphogen Nodal.
• To propose a strategic approach to overcome melanoma's therapeutic challenges.

Main Methods:

• Review of recent studies on CSC markers (Nodal, CD133) and drug resistance markers (ABCA1).
• Analysis of Nodal's role in aggressive melanoma phenotypes.
• Evaluation of Nodal as a therapeutic target.

Main Results:

• Nodal, CD133, and ABCA1 are associated with aggressive melanoma phenotypes and drug resistance.
• Targeting Nodal shows promise as a therapeutic strategy.
• Melanoma utilizes multiple survival mechanisms, including heterogeneity and plasticity.

Conclusions:

• Targeting Nodal in combination with standard-of-care therapy is a promising option for metastatic melanoma.
• A strategic approach is needed to address tumor heterogeneity, plasticity, and resistance.
• Effective targeting strategies are crucial to prevent relapse, progression, and metastasis.